Groowe Groowe / Newsroom / TAK
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

TAK News

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Anumana Appoints Kevin Ballinger and Jean-Luc Butel to Board of Directors

businesswire.com
CVRX TAK ICON RANI BAX MDT BDX JNJ

$21.93 Bn Colorectal Cancer Drugs Global Market Trends, Opportunities and Strategies, 2019-2024, 2025-2029F, 2034F

globenewswire.com
MRK AMGN BMY LLY TAK PFE SNY

Psoriasis Market to Exhibit Growth at a CAGR of 1.7% During the Forecast Period (2025-2034), Owing to Continuous Innovation in Biologic Therapies and Approval of Oral Small Molecules | DelveInsight

prnewswire.com
TAK JNJ CANF AMGN ABBV NVS BMY AZN BHC LLY UCB LEO REGN XBI IBB JAZZ MRK SNY GILD INCY PFE LULU PRTH DRH BIIB TEVA ARCT HRMY CRSP NTLA EDIT SNOW DDOG CRM GOOG MSFT AAPL AMZN TSLA NVDA META NFLX DIS CMCSA VZ T KO PEP MCD SBUX HD EXAS ILMN BNTX MRNA XOM CVX BA CAT GE IBM INTC CSCO ADBE QCOM AMAT MU ORCL ACN COST WMT TGT LOW HON GD LMT RTX BAX

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

businesswire.com
TAK PTGX

Celiac Disease Market Report 2025-2035: Drivers, Challenges, Opportunities, Industry Trends and Case Studies

globenewswire.com
TAK IMUX PFE

The Skin of Color Society (SOCS) Reports an Impactful Year of Progress, Expansion, and Innovation Toward Advancing Knowledge and Excellence in Patient Care

prnewswire.com
JNJ LLY SNY REGN ABBV AERO BIIB GALT TAK ELMD PFE SUN INCY BMY ARQT UCB

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

businesswire.com
TAK

Celiac Disease Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

globenewswire.com
TAK AMGN JNJ BMY

Public Affairs and Patient Advocacy Leader Kim Isenberg Joins National Organization for Rare Disorders Board of Directors

prnewswire.com
SNY TAK

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

businesswire.com
PTGX TAK